Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530685 | 0.92 | KDM4E (0.53) | PARP10MAOBLTA4HKDM4ESMN1; SMN2 | |
| SCHEMBL17122910 | 0.82 | LTA4H (0.48) | PARP10LTA4HL3MBTL1 | |
| SCHEMBL652824 | 0.82 | L3MBTL1 (0.67) | LTA4HALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL8302869 | 0.81 | LTA4H (0.54) | MAOBLTA4HALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4689283 | 0.81 | CYP1A2 (0.54) | ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL8113416 | 0.81 | L3MBTL1 (0.46) | PARP10LTA4HL3MBTL1PDK2 | |
| SCHEMBL881471 | 0.81 | L3MBTL1 (0.70) | PARP10LTA4HL3MBTL1 | |
| SCHEMBL1117015 | 0.81 | MAPT (0.66) | PARP10ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1310073 | 0.81 | LTA4H (0.50) | PARP10MAOBLTA4HALDH1A1KDM4E | |
| SCHEMBL1116911 | 0.80 | ALDH1A1 (0.55) | MAOBLTA4HALDH1A1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2209473-B1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| CN-102271678-A | 2-acylaminopropanol type glucosylceramide synthase inhibitors | — | 2011-12-07 | — | — | CN | disclosed |